Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Characterizing the Host Immune Response to AAV Vectors in Naive and Pre-exposed Non-Human Primates

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Characterizing the Host Immune Response to AAV Vectors in Naive and Pre-exposed Non-Human Primates

CELL & GENE | RNA | BIOLOGICS

Characterizing the host immune response to adeno-associated virus (AAV) vectors in non-human primates (NHPs) is a primary determinant of clinical success. The main challenge is translating preclinical immunogenicity data into accurate predictions of safety and efficacy in a human population with variable pre-existing AAV immunity. Our approach quantifies both humoral and cell-mediated immune responses in naive and seropositive NHP cohorts to generate a comprehensive data package that directly supports clinical trial design and regulatory submissions, targeting an 18-24 month IND timeline.

    What is the primary challenge with pre-existing AAV immunity?

    A: Pre-existing neutralizing antibodies (NAbs) against the AAV capsid can significantly inhibit vector transduction, reducing or eliminating therapeutic efficacy. Assessing NAb titers is a standard part of subject screening for many clinical trials.

    How are humoral and cellular immune responses assessed?

    A: Humoral immunity is evaluated using ELISA to detect total binding antibodies (e.g., IgG) and validated cell-based assays to measure NAb activity. Cellular immunity is assessed via functional assays like ELISpot or intracellular cytokine staining (ICS) to quantify capsid-specific T-cell responses.

    Why use both naive and pre-exposed NHP cohorts?

    A: This dual-cohort design models the human population, where AAV seroprevalence is high. It allows for the evaluation of the primary immune response in naive subjects and the risk of a rapid, memory-based (anamnestic) immune response in pre-exposed subjects, which can impact long-term expression and safety.

    What key endpoints are measured in these NHP studies?

    A: Core endpoints include vector genome biodistribution in target and non-target tissues, transgene expression levels, comprehensive immune cell profiling, cytokine analysis, and detailed histology of relevant tissues to assess for inflammatory infiltrates.

Translational AAV Immunogenicity Assessment

Predicting the human immune response to AAV vectors is a significant variable in gene therapy development. The non-human primate model provides the most predictive system for evaluating potential immunotoxicities and efficacy limitations prior to first-in-human studies. An effective NHP study design must account for species-specific biological factors that influence vector performance and host immune interactions.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Species-Specific Transduction and Its Predictive Value

Translational success depends on selecting a preclinical model that accurately reflects human physiology. For instance, studies have demonstrated that AAV liver transduction patterns can be inverted between species. While some models show pericentral hepatocyte transduction, NHPs exhibit a periportal pattern, a finding with direct implications for predicting efficacy and potential toxicity for liver-directed gene therapies (PMID: 21778099). This underscores the use of NHP models to correctly inform human dose selection and anticipate clinical outcomes.

Our >100,000 sq ft facility is fully equipped to conduct these complex, large-animal studies under GxP conditions.

)

Modeling Durable Immunity for Advanced Platforms

Beyond initial efficacy, understanding the durability of the immune response is a key objective. NHP models have proven highly effective in assessing long-term immunogenicity for AAV-based platforms, including vaccines. Research has shown that AAV-vectored antigens can elicit potent and durable protective immunity in NHPs, providing a robust framework for evaluating next-generation therapeutic constructs (PMID: 34428428). This capability is directly applicable to gene therapy programs where sustained transgene expression is the goal.

“Wonderful services. Excellent team to work with. Vast knowledge in all aspects of vector production and analytics.”
— Biotech Partner

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

A scientist in protective gear pipetting a sample into a vial within a sterile laboratory hood.

Methodological Framework for Immunogenicity Assessment

A structured study design generates a comprehensive IND-enabling data package. Our NHP programs are organized to provide a clear and thorough evaluation of the immune response profile.

  • Baseline Characterization: All subjects undergo screening for pre-existing NAbs to the AAV capsid serotype of interest, allowing for precise stratification into naive and pre-exposed cohorts.

  • Longitudinal Monitoring: Following vector administration, serial blood samples are collected to monitor the kinetics of both humoral (binding and neutralizing antibodies) and cellular (T-cell) immune responses over time.

  • Terminal Analysis: At the study endpoint, a full necropsy is performed. Key assessments include quantitative PCR for vector genome biodistribution, measurement of transgene expression in target tissues, and a comprehensive histology analysis to identify any vector-related pathology.

Animal Welfare and Compliance

All in vivo studies are conducted in full compliance with USDA regulations. Our scientific and veterinary staff are committed to the principles of the 3Rs (Replacement, Reduction, and Refinement) to ensure the highest standards of animal welfare, which extends to the use of AAALAC-accredited facilities through our strategic partners.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities